Search the Newsreel

NeoGenomics (NEO) Is Down 7.7% After DOJ Settlement On Legacy Agreements – Has The Bull Case Changed?

NeoGenomics recently finalized a civil settlement with the U.S. Department of Justice for nearly $10 million, resolving a compliance overhang after an internal investigation into past agreements. Despite a 7.7% stock drop, the settlement amount is manageable given prior reserves, and the company is …

American Capital Management Inc. Trims Stock Position in Neogen Corporation $NEOG

American Capital Management Inc. significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 90.4% in the first quarter, selling over 1.2 million shares. Despite this, other institutional investors like JPMorgan Chase & Co. and Bessemer Group Inc. increased their holdings, with institutional investors now …

Neogen (NEOG) Reports Q2: Everything You Need To Know Ahead Of Earnings

NeoGenomics | 10-Q: Q2 2026 Earnings Report

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NeoGenomics (NASDAQ:NEO) reported strong Q2 CY2026 results, exceeding Wall Street's expectations for revenue and adjusted EPS. The oncology diagnostics company's revenue grew 11.2% year-on-year to $201.7 million, with an adjusted EPS of $0.05. NeoGenomics also slightly raised its full-year revenue and adjusted EPS guidance, …

NEOGENOMICS ($NEO) Releases Q2 2026 Earnings, Stock Rises

NeoGenomics pays $10 million to settle kickback allegations after self-disclosing below-market deals

NeoGenomics Laboratories has agreed to pay nearly $10 million to settle allegations that it violated the False Claims Act. The settlement comes after NeoGenomics self-disclosed providing below-market-value consulting services to healthcare providers who referred patients for laboratory testing and paying variable referral-based compensation to …

First Light Asset Management LLC Has $72.20 Million Position in NeoGenomics, Inc. $NEO

First Light Asset Management LLC slightly reduced its stake in NeoGenomics, Inc. by 3% in Q1, but it remains its third-largest position, valued at $72.2 million. NeoGenomics, a cancer-focused genetic testing provider, reported strong Q1 revenue growth of 11.3% year-over-year but remains unprofitable. Analyst …

Neogen Corp (NEOG) Cash Flow

This article provides a detailed historical cash flow statement for Neogen Corp (NEOG), including operating, investing, and financing cash flows, presented quarterly and annually. It outlines key cash flow metrics such as net income, operating gains/losses, deferred tax, changes in working capital, capital expenditures, …

Neogen Corp (NEOG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an historical overview of dividends and stock splits for Neogen Corp (NEOG). It notes that Neogen has not distributed any dividends in the past five years. The company has had one recorded stock split event, a 1-for-2 split on May 12, …

NEO|Neogenomics Inc|Price:13.890|Chg%:-0.350

This article provides an overview of Neogenomics Inc (NEO) stock performance and basic financial information. It shows the current stock price, market cap, and a note that a stock score is unavailable due to insufficient data. The article also mentions various sections like Financials, …

Healthcare of Ontario Pension Plan Trust Fund Sells 193,454 Shares of Neogen Corporation $NEOG

The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Neogen Corporation by 5.5% in the first quarter, selling 193,454 shares and now owning 3,297,346 shares valued at $30.63 million. Despite this, other institutional investors like Huntington National Bank and ProShare Advisors …

NEO Income Statement

This article from TradingKey provides an overview of Neogenomics Inc.'s (NEOUSD) income statement. It explains how to interpret quarterly and annual financial data, defines key metrics like YOY, and highlights important figures such as revenue, gross profit, operating profit, and EPS for stock analysis. …

Neogen Chemicals releases Q1FY27 earnings call recording for stakeholder review

Neogen Chemicals Publishes Q1 FY27 Earnings Presentation for Investors

Neogen Chemicals revenue rises 37% in Q1FY27 as battery expansion plans take shape

NEOGEN: Q1 FY 2027 saw record revenue and margin expansion, with upgraded guidance for both core and battery businesses

NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

Neogen Corporation (NASDAQ:NEOG) Receives Average Rating of "Hold" from Brokerages

Neogen Corporation (NASDAQ:NEOG) has an average "Hold" rating from six brokerages, with one analyst issuing a sell rating, three a hold, and two a buy, and an average 12-month price target of $10.6667. Recent analyst reports include an upgrade from "hold" to "buy" by …

Neogen Chemicals Q1FY27 profit rises 32%, Board approves ₹600 crore fund raise

NEOG|Neogen Corp|Price:9.400|Chg%:-0.210

This article provides a comprehensive stock analysis of Neogen Corp (NEOG) from TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It details the company's scores across financial health, valuation, earnings forecast, price momentum, institutional …

Neogen Corp (NEOG) Valuation: PE, PB & Fair Value Analysis

Neogen Corp (NEOG) currently holds a valuation score of 7.95, placing it 121 out of 200 in the Healthcare Equipment & Supplies industry. Its P/E ratio is -3.35, significantly below its recent high and above its recent low. However, P/B, P/S, and P/CF data …

Neogen Corp (NEOG) Institutional Confidence

Neogen Corp (NEOG) has a strong institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional holdings have increased by 6.66% quarter-over-quarter, with Ron Baron being the largest institutional shareholder. Several major institutional investors show varying activity, such …

Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Raises Target Price to $16

Benchmark Co. has reiterated its Buy rating on NeoGenomics (NEO.US) and increased its price target to $16. This adjustment reflects the firm's continued confidence in the company's prospects.

NEO Maintained by Benchmark -- Price Target Raised to $16.00

Benchmark maintained a Buy rating on NeoGenomics (NEO) and raised its price target to $16.00, up from the previous $11.00. GuruFocus indicates that NEO is currently undervalued by 14.7% with a GF Value™ of $16.69 and holds a solid GF Score™ of 72/100, though …

Neogen Chemicals Reports ₹19.4 Crore Standalone Q1 Profit, To Raise ₹600 Crore Via QIP

NeoGenomics Inc. (NG9) Q2 2025 Earnings Report - Results, Call & Slides

NeoGenomics Inc. (NG9) released its Q2 2025 earnings report, indicating a beat on EPS with €0.03 against a consensus of €0.02, but missed revenue expectations at €159.26M versus an anticipated €160.42M. The company experienced a 10.23% year-over-year revenue growth. The earnings call was scheduled …

Neogen (NEOG) Expected to Post Earnings on Thursday

Neogen (NASDAQ:NEOG) is expected to announce its Q4 2026 earnings before the market opens on Thursday, July 30th. Analysts project earnings of $0.05 per share and revenue of $212.35 million. The company's stock has an average "Hold" rating from analysts with an average price …

Illinois Municipal Retirement Fund Invests $1.17 Million in Neogen Corporation $NEOG

The Illinois Municipal Retirement Fund (IMRF) recently invested $1.17 million in Neogen Corporation (NASDAQ:NEOG) by purchasing 126,139 shares during the first quarter. This comes as institutional and hedge fund ownership of Neogen stands at 96.73%, with other major investors also adjusting their stakes. Analysts …

NeoGenomics, Inc. Files 8-K Report on July 20, 2026 – Key Corporate and Financial Disclosure Details

NeoGenomics, Inc. (NASDAQ: NEO) has finalized a civil settlement with the U.S. Department of Justice for $9,813,260, resolving an investigation into consulting services. The settlement amount is less than the $11.2 million reserve previously accrued by the company, suggesting a positive financial outcome. This …

NeoGenomics (NEO) to Post Quarterly Earnings on Tuesday

NEOGENOMICS INC 8-K — Jul 20, 2026

This article reports on an 8-K filing by NEOGENOMICS INC on July 20, 2026. It highlights that the filing includes "Other events (+2 more items)". The financial document is available for viewing on SEC.gov.

NeoGenomics Settles DOJ Investigation Related to Laboratory Collaboration Program

NeoGenomics, Inc. announced a settlement with the U.S. Department of Justice (DOJ) regarding an investigation into its laboratory collaboration program. The settlement will result in a payment of $30 million by NeoGenomics, resolving claims related to potential False Claims Act violations. While the company …

NeoGenomics finalizes $9.81M DOJ settlement over voluntary OIG-HHS disclosure

NeoGenomics has finalized a civil settlement with the Department of Justice on behalf of OIG-HHS, agreeing to pay $9,813,260 plus interest to resolve an investigation into certain consulting services related to its Laboratory Collaboration Initiative. The company self-disclosed the issue in November 2021 and …

NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation

NeoGenomics has agreed to pay $9.8 million to settle allegations from the U.S. Justice Department that it violated the False Claims Act. The allegations center on the company providing laboratory consulting services below fair market value and paying referral-based compensation to independent consultants, which …

Neogen (NEOG) to Release Q4 2026 Financial Results on July 30

Neogen Corporation (NEOG) is set to release its Q4 and full fiscal year 2026 financial results on July 30, with analysts projecting revenues between $150M-$155M for Q4 and around $590M for the full year. GuruFocus assesses NEOG as 16.8% undervalued with a GF Value …